DNA Pharma Companies Trials 
The Pharma Data
DECEMBER 20, 2020
UK drug developer Scancell said it has chosen a COVID-19 vaccine candidate, SN14, from more than a dozen potential products to advance to a clinical trial. . SN14 works by targeting the coronavirus’ nucleocapsid and spike proteins to prevent viral replication using the company’s ImmunoBody DNA vaccine technology.
Codon
FEBRUARY 13, 2024
1 Yet even after more than two decades of research, media hype, and dozens of clinical trials and biotech start-ups that have come and gone, phage therapy has not scaled. No phage-based therapeutic has reached the latter stages of the clinical trial pipeline (where promising results lead to an expanded trial involving thousands of patients).
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
DrugBaron
OCTOBER 17, 2022
Examples, such as post-hoc analyses of failed trials, are today too numerous to even be notorious. This is the unifying narrative that companies, particularly biotechs, tend to weave around their assets to make them palatable to investors. In practice, this looks much more like a traditional pharma company than a biotech.
Vial
FEBRUARY 19, 2024
As we put it in first in human (trials), and we saw responses, it was super exciting to be able to navigate the landscape and where to position it for the patient benefit. Also, payloads that are permeable payloads and specifically microtubule inhibitors or DNA alkylators or chemo. Rich McCormick: That’s impressive teamwork.
The Pharma Data
OCTOBER 14, 2020
The designation of lanifibranor as a Breakthrough Therapy for the treatment of NASH follows the publication in June 2020 of positive topline results from Inventiva’s NATIVE Phase IIb clinical trial with lanifibranor in NASH patients. The trial plans to evaluate safety, tolerability, cytokine profile and efficacy parameters.
The Pharma Data
MAY 13, 2021
Unfortunately, I learned the hard way that the “Big Pharma” companies don’t care about their patients. And the best part was this: over the two year trial, the treatment had ZERO side effects making it completely safe. Stimulates DNA and RNA synthesis. It’s all about the bottom line, at any cost.
The Pharma Data
DECEMBER 16, 2020
During Phase III trials, one of the cohorts was administered one and a half doses, as opposed to two full doses. the company is exploring other ways to combat COVID-19. AstraZeneca is partnering with INOVIO and multiple universities to advance INOVIO’s innovative DNA-encoded monoclonal antibody (dMAb) technology.
Expert insights. Personalized for you.
52 
Let's personalize your content